The latest market price of Erlotinib in 2025

Erlotinib (Erlotinib) is a tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). It is mainly used to treat specific gene-mutated non-small cell lung cancer (NSCLC) and in combination with gemcitabine for pancreatic cancer. With the popularization of EGFR mutation detection technology, erlotinib has become an important first-line treatment option for patients with positive EGFR sensitive mutations. Its mechanism of action is to block the proliferation and metastasis of tumor cells by inhibiting the activation of the EGFR signaling pathway, which has a significant effect on delaying disease progression and improving survival time. In clinical practice, the efficacy of erlotinib is more prominent, especially in Asian populations, women, and never-smoking patients with lung adenocarcinoma.

In terms of indications, erlotinib is approved for the treatment of locally advanced or metastatic non-small cell lung cancer, especially patients with EGFR sensitive mutations. For patients with pancreatic cancer, it is often used in combination with gemcitabine, which can extend survival to some extent. In recent years, with the emergence of immunotherapy and the new generation of EGFR-TKI, the positioning of erlotinib in clinical treatment has changed, but it is still widely used in many countries and regions.

In terms of price, erlotinib has been launched in China and is included in medical insurance, which greatly reduces the burden on patients. At present, the selling price of Tarceva in China varies according to different regions and specifications. After medical insurance reimbursement, the patient's out-of-pocket payment ranges from tens of yuan to six or seven hundred yuan. The specific price depends on local medical insurance policies and pharmacy conditions. In foreign markets, in addition to original drugs, there are also multiple versions of generic drugs circulating. Among them, Indian generic drugs are mature in production and priced at a low price. The price is about RMB 800, and their pharmaceutical ingredients are consistent with the original drugs. Some countries, such as Türkiye and Bangladesh, also have related generic versions, and the price is slightly lower than the original drug. It should be noted that the price of imported generic drugs will be affected by exchange rate changes and will fluctuate to a certain extent.

Overall, with its clear mechanism of action and clinical benefits, erlotinib remains one of the important treatment options for EGFR mutant NSCLC With the introduction of medical insurance coverage and generic drugs, patient accessibility has significantly improved, which has also alleviated financial pressure on more families.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib